Trial Information

Summary: A Phase III randomized, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinoma

The purpose of this study is to test if a new drug, sorafenib, is an effective treatment for patients with liver cancer. Patients qualify for participation in this study because they have advanced liver (hepatocellular) cancer (HCC) that cannot be removed by surgery. Sorafenib is designed to stop the growth of cancer cells. The study is considered research because the study drug, sorafenib, has not been approved by the FDA.
This is a placebo-controlled study. In this study, neither the patients or the study doctor will know if patients are receiving sorafenib or a placebo (a pill with no active medication).
All study medications and procedures are provided for free.

No Compensation Provided

Patient Inclusion/Exclusion Criteria:

You may be eligible to participate if you
-are male or female at least 18 years old
-have been diagnosed with advanced liver cancer
-can swallow oral medication (tablets)
-meet additional criteria
*You may be eligible even if you have had past surgeries and/or treatment for your cancer.

You will not be eligible to participate if you
-are receiving dialysis
-are pregnant or breastfeeding
-are HIV positive

If you would like to learn more about participating in this study, please send an e-mail message using the form below.